Mir-roring hypoxia in EGFR-TKI tolerance

George A. Calin; Barbara Pardini

doi:10.1038/s42255-019-0057-4

Mir-roring hypoxia in EGFR-TKI tolerance

George A. Calin, Barbara Pardini

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

Understanding the mechanisms by which tumour cells adapt or succumb to targeted therapies is crucial to improving cancer treatment. A study in this issue of Nature Metabolism demonstrates how microRNAs, metabolic pathways and pseudohypoxia play a major role in the drug tolerance to epidermal growth factor receptor (EGFR) inhibitors in lung adenocarcinoma.

Original language	English (US)
Pages (from-to)	418-419
Number of pages	2
Journal	Nature Metabolism
Volume	1
Issue number	4
DOIs	https://doi.org/10.1038/s42255-019-0057-4
State	Published - Apr 1 2019

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Physiology (medical)
Internal Medicine
Cell Biology
General Medicine

Access to Document

10.1038/s42255-019-0057-4

Cite this

@article{d17d9e37bb9a401681e738a11b31d37e,

title = "Mir-roring hypoxia in EGFR-TKI tolerance",

abstract = "Understanding the mechanisms by which tumour cells adapt or succumb to targeted therapies is crucial to improving cancer treatment. A study in this issue of Nature Metabolism demonstrates how microRNAs, metabolic pathways and pseudohypoxia play a major role in the drug tolerance to epidermal growth factor receptor (EGFR) inhibitors in lung adenocarcinoma.",

author = "Calin, {George A.} and Barbara Pardini",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Limited.",

year = "2019",

month = apr,

day = "1",

doi = "10.1038/s42255-019-0057-4",

language = "English (US)",

volume = "1",

pages = "418--419",

journal = "Nature Metabolism",

issn = "2522-5812",

publisher = "Springer Berlin",

number = "4",

}

TY - JOUR

T1 - Mir-roring hypoxia in EGFR-TKI tolerance

AU - Calin, George A.

AU - Pardini, Barbara

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Understanding the mechanisms by which tumour cells adapt or succumb to targeted therapies is crucial to improving cancer treatment. A study in this issue of Nature Metabolism demonstrates how microRNAs, metabolic pathways and pseudohypoxia play a major role in the drug tolerance to epidermal growth factor receptor (EGFR) inhibitors in lung adenocarcinoma.

AB - Understanding the mechanisms by which tumour cells adapt or succumb to targeted therapies is crucial to improving cancer treatment. A study in this issue of Nature Metabolism demonstrates how microRNAs, metabolic pathways and pseudohypoxia play a major role in the drug tolerance to epidermal growth factor receptor (EGFR) inhibitors in lung adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85073644467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073644467&partnerID=8YFLogxK

U2 - 10.1038/s42255-019-0057-4

DO - 10.1038/s42255-019-0057-4

M3 - Comment/debate

C2 - 32694876

AN - SCOPUS:85073644467

SN - 2522-5812

VL - 1

SP - 418

EP - 419

JO - Nature Metabolism

JF - Nature Metabolism

IS - 4

ER -

Mir-roring hypoxia in EGFR-TKI tolerance

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this